ArticleAnnals of medicine2025
Survival and pathological response in pancreatic ductal adenocarcinoma after preoperative therapy with PD-1 blockade plus chemoradiotherapy followed by surgical resection.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Efficacy and safety of pembrolizumab, lenvatinib, and reduced-dose gemcitabine/oxaliplatin as initial treatment for advanced biliary tract cancer: a multicenter, single-arm, prospective, phase II study.Journal for immunotherapy of cancer · 2026Trial
- Neoadjuvant Early Stereotactic Body Radiation Therapy Followed by Chemoimmunotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer.Advances in radiation oncology · 2026Article
- Evaluating the prognostic significance of lymph node yield in resected pancreatic adenocarcinoma: a population-based study.World journal of surgical oncology · 2026Article
- Complete Pathological Response to Neoadjuvant Treatment in Pancreatic Ductal Adenocarcinoma-Can We Achieve a Long-Term Survival? A Narrative Review.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeoadjuvant PD-1 blockade plus chemoradiotherapy has resulted in improved clinical response in pancreatic ductal adenocarcinoma (PDAC); however, the effects on pathological response (PR) and survival remain unknown. This study was to identify the survival and PR of patients with PDAC undergoing surgery after neoadjuvant treatment (NAT) with PD-1 blockade plus chemoradiotherapy.
methodsA retrospective cohort study was performed for PDAC patients undergoing resection after NAT, analyzing PR and survival prediction using clinicopathological and survival data.
results47 patients were enrolled with 26 received neoadjuvant PD-1 blockade plus chemoradiotherapy (combined group) and 21 received PD-1 blockade plus chemotherapy (non-combined group). 6 patients (23.1%) and no patients achieved complete PR (CPR) in the combined and non-combined group. Age and tumor size decrease were independently associated with PR assessed by the CAP and MDACC system (
conclusionsNAT with PD-1 blockade plus chemoradiotherapy was associated with a higher CPR rate in resected PDAC. Age and tumor size decrease were predictive factors for PR. PV/SMV invasion, resectability status, and preoperative CA 19-9 levels were independent prognostic factors for survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.